VTRS
Q3 2026 EPS Estimate
$0.62
Aug 6, 2026 · Reports before open
Revenue Estimate
$3.66B
FY2026E EPS$2.47
FY2027E EPS$2.67

Analyst Sentiment

Wall St. Consensus
Hold
13 analysts·Moderate coverage
56
Score
4 Buy (31%)8 Hold (62%)1 Sell (7%)
Rating Breakdown
Strong Buy
00%
Buy
431%
Hold
862%
Sell
18%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$12.00
-26.5%
Consensus
$18.00
+10.2%
Bull
$22.00
+34.7%
12-Month Target Range13 analysts
$12.00$18.00$22.00
Current $16.33Consensus
Current Price
$16.33
Upside to Consensus
$1.67

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+1.82%
EPS+8.20%
FY2028
Rev+2.09%
EPS+11.26%
FY2029
Rev-2.57%
EPS
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028EFY2029E
Revenue Avg$14.78B$15.05B$15.37B$14.97B
Low$14.73B$14.89B$15.35B$14.85B
High$14.84B$15.25B$15.38B$15.11B
EBITDA Avg$3.07B$3.12B$3.19B$3.11B
Low$3.06B$3.09B$3.19B$3.08B
High$3.08B$3.16B$3.19B$3.14B
EBIT Avg$88M$90M$92M$89M
Low$88M$89M$92M$89M
High$89M$91M$92M$90M
Net Income Avg$2.91B$3.13B$3.48B
Low$2.80B$3.06B$1.37B
High$3.02B$3.20B$5.59B
EPS Avg$2.47$2.67$2.97
Low$2.39$2.61$1.17
High$2.58$2.73$4.78
Analysts (Rev / EPS)6 / 56 / 55 / 22 /
Quarterly
MetricQ2 2026Q3 2026Q4 2026Q1 2027Q2 2027Q3 2027Q4 2027
Revenue Avg$3.66B$3.82B$3.78B$3.60B$3.74B$3.92B$3.84B
Low$3.64B$3.78B$3.70B$3.52B$3.67B$3.84B$3.76B
High$3.68B$3.84B$3.83B$3.65B$3.80B$3.98B$3.89B
EBITDA Avg$760M$794M$784M$747M$777M$814M$796M
Low$756M$785M$767M$731M$761M$797M$780M
High$765M$798M$795M$757M$788M$826M$808M
EBIT Avg$22M$23M$23M$21M$22M$23M$23M
Low$22M$23M$22M$21M$22M$23M$22M
High$22M$23M$23M$22M$23M$24M$23M
Net Income Avg$713M$761M$730M$705M$751M$796M$765M
Low$693M$750M$710M$686M$731M$775M$744M
High$724M$776M$743M$719M$765M$811M$779M
EPS Avg$0.61$0.65$0.62$0.60$0.64$0.68$0.65
Low$0.59$0.64$0.60$0.58$0.62$0.66$0.63
High$0.62$0.66$0.63$0.61$0.65$0.69$0.66
Analysts (Rev / EPS)5 / 65 / 52 / 12 / 12 / 12 / 12 / 1

Earnings Surprises

Recent Analyst Actions

May 19, 2026Barclays
Viatris price target raised to $22 from $17 at Barclays
Target:$22.00
+33.3%from $16.50
May 8, 2026Truist Financial
Viatris price target raised to $20 from $18 at Truist
Target:$20.00
+18.0%from $16.95
Feb 9, 2026UBS
Viatris upgraded to Buy from Neutral at UBS
Target:$18.00
+23.5%from $14.58
Jan 28, 2026Piper Sandler
Viatris price target raised to $12 from $9 at Piper Sandler
Target:$12.00
-8.5%from $13.12
Jan 16, 2026Argus Research
Argus upgrades Viatris to Buy on expected buybacks, debt reduction
Target:$15.00
+16.8%from $12.84
Jan 7, 2026Truist Financial
Viatris price target raised to $16 from $15 at Truist
Target:$16.00
+29.0%from $12.40
Oct 15, 2025Truist Financial
Viatris initiated with a Buy at Truist
Target:$15.00
+51.1%from $9.93
Jul 19, 2024Jefferies
Viatris reinstated with a Buy at Jefferies
Target:$15.00
+27.4%from $11.77
Mar 28, 2024Piper Sandler
Viatris (VTRS) PT Raised to $13 at Piper Sandler on latest Idorsia deals
Target:$13.00
+9.9%from $11.83
Jun 26, 2023Piper Sandler
Check Out 3 Health Care Stocks With Over 4% Dividend Yields From Wall Street's Most Accurate Analysts
Target:$10.00
+1.7%from $9.84
Feb 1, 2023Barclays
Barclays Maintains Overweight on Viatris, Lowers Price Target to $15
Target:$15.00
+23.4%from $12.16
Nov 9, 2022UBS
UBS Upgrades Viatris (VTRS) to Neutral
Target:$12.00
+10.8%from $10.83
Jun 13, 2022UBS
Viatris initiated with a Sell at UBS
Target:$9.00
-16.4%from $10.77
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.